CSNK2A1 and osteosarcoma: CSNK2A1-positivity predicted a 10.147-fold (95% CI; 2.320–44.385, p = 0.002) greater risk of death and a 12.179-fold (95% CI; 2.777–53.407, p < 0.001) greater risk of relapse or death in osteosarcoma patients (Table 3).